Barclays
PRVB

Barclays’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Barclays’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,846
Closed -$263K – 5490
2022
Q4 		$263K Buy
+24,846
New +$200K ﹤0.01% 3698
2021
Q4 		– Sell
-77,683
Closed -$497K – 4884
2021
Q3 		$497K Buy
77,683
+70,667
+1,007% +$454K ﹤0.01% 3204
2021
Q2 		$59K Buy
7,016
+6,698
+2,106% +$54K ﹤0.01% 4063
2021
Q1 		$3K Buy
318
+123
+63% +$1.73K ﹤0.01% 4542
2020
Q4 		$3K Sell
195
-22,549
-99% -$338K ﹤0.01% 4806
2020
Q3 		$292K Buy
+22,744
New +$287K ﹤0.01% 3599
2020
Q1 		– Sell
-1
Closed – – 6588
2019
Q4 		$0 Sell
1
-3,769
-100% -$33.6K ﹤0.01% 6978
2019
Q3 		$26K Sell
3,770
-4,048
-52% -$40.9K ﹤0.01% 6154
2019
Q2 		$95K Buy
+7,818
New +$42.6K ﹤0.01% 5734

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Barclays's PRVB Position: Q1 2023 in Review

Barclays sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 24,846 shares — an estimated $263K sold.

Barclays first reported a position in PRVB in Q2 2019 and held it in 9 quarters. The position peaked at $497K in Q3 2021. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Barclays reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Barclays sold 24,846 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $263K.
  • Barclays first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 9 quarters.
  • Barclays's Provention Bio, Inc. Common Stock position peaked at $497K in Q3 2021.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.